DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Voss MH. et al
Results from a randomized phase ½ trial evaluating the safety and antitumor activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma.
IKCS 2019 Posterpräsentation
Access:
We do not assume any responsibility for the contents of the web pages of other providers.